Telesis Bio, Inc. (NASDAQ:TBIO) Sees Large Increase in Short Interest

Telesis Bio, Inc. (NASDAQ:TBIOGet Free Report) saw a significant growth in short interest in May. As of May 15th, there was short interest totalling 17,500 shares, a growth of 386.1% from the April 30th total of 3,600 shares. Currently, 3.8% of the company’s stock are sold short. Based on an average trading volume of 38,000 shares, the short-interest ratio is presently 0.5 days.

Telesis Bio Stock Down 0.9 %

Shares of TBIO stock traded down $0.03 during trading hours on Thursday, hitting $3.67. 12,731 shares of the company were exchanged, compared to its average volume of 35,500. The business has a 50 day moving average of $6.17 and a two-hundred day moving average of $6.92. The company has a quick ratio of 3.08, a current ratio of 3.65 and a debt-to-equity ratio of 22.76. Telesis Bio has a 52 week low of $3.33 and a 52 week high of $39.24.

Telesis Bio (NASDAQ:TBIOGet Free Report) last issued its quarterly earnings data on Thursday, March 28th. The company reported ($4.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.50) by $0.36. The company had revenue of $6.98 million during the quarter. Telesis Bio had a negative net margin of 183.66% and a negative return on equity of 359.32%.

Telesis Bio Company Profile

(Get Free Report)

Telesis Bio, Inc, a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications.

Featured Articles

Receive News & Ratings for Telesis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telesis Bio and related companies with's FREE daily email newsletter.